Novartis' Phase II study of skin cancer drug sonidegib meets primary endpoint

Novartis has reported that the Phase II study evaluating its investigational oral compound LDE225 (sonidegib) in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of tr…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news